Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C

References

• ChakETalalAHShermanKESchiffERSaabSHepatitis C virus infection in USA: an estimate of true prevalenceLiver Int20113181090110121745274
   PubMed Web of Science ®Google Scholar
• DavisGLAlterMJEl-SeragHPoynardTJenningsLWAging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progressionGastroenterology20101382513521521.e51151619861128
   PubMed Web of Science ®Google Scholar
• RazaviHElkhouryACElbashaEChronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology20135762164217023280550
   PubMed Web of Science ®Google Scholar
• MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet2001358928695896511583749
   PubMed Web of Science ®Google Scholar
• NicotFAlricLBarangeKInfluence of HCV genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus ribavirin therapyJ Med Virol201183343744421264864
   PubMed Web of Science ®Google Scholar
• FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
   PubMed Web of Science ®Google Scholar
• SaabSJacksonCNietoJFrancoisFHepatitis C in African AmericansAm J Gastroenterol20141091015761584 quiz 1575, 158525178700
   PubMed Web of Science ®Google Scholar
• SaabSRheemJSundaramVHepatitis C infection in the elderlyDig Dis Sci201560113170318026008618
   PubMed Web of Science ®Google Scholar
• KimAIDornABouajramRSaabSThe treatment of chronic hepatitis C in HIV-infected patients: a meta-analysisHIV Med20078531232117561878
   PubMed Web of Science ®Google Scholar
• GhanyMGLiangTJCurrent and future therapies for hepatitis C virus infectionN Engl J Med2013369767968023944318
   PubMed Web of Science ®Google Scholar
• KohliAShafferAShermanAKottililSTreatment of hepatitis C: a systematic reviewJAMA2014312663164025117132
   PubMed Web of Science ®Google Scholar
• PearlmanBLTraubNSustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much moreClin Infect Dis201152788990021427396
   PubMed Web of Science ®Google Scholar
• BrunoSStroffoliniTColomboMSustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective studyHepatology200745357958717326216
   PubMed Web of Science ®Google Scholar
• SingalAKSinghAJaganmohanSAntiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosisClin Gastroenterol Hepatol20108219219919879972
   PubMed Web of Science ®Google Scholar
• van der MeerAJVeldtBJFeldJJAssociation between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosisJAMA2012308242584259323268517
   PubMed Web of Science ®Google Scholar
• YounossiZMKanwalFSaabSThe impact of hepatitis C burden: an evidence-based approachAliment Pharmacol Ther201439551853124461160
   PubMed Web of Science ®Google Scholar
• LawitzEGaneEPearlmanBEfficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialLancet201538599731075108625467591
   PubMed Web of Science ®Google Scholar
• SulkowskiMHezodeCGerstoftJEfficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trialLancet201538599731087109725467560
   PubMed Web of Science ®Google Scholar
• ZeuzemSGhalibRReddyKRGrazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trialAnn Intern Med2015163111325909356
   PubMed Web of Science ®Google Scholar
• ButiMGordonSCZuckermanEGrazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGEClin Infect Dis2016621323626371152
   PubMed Web of Science ®Google Scholar
• FornsXGordonSCZuckermanEGrazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agentJ Hepatol201563356457225895428
   PubMed Web of Science ®Google Scholar
• MaruyamaAPartoviNYoshidaEMErbSRAzalgaraVMHussainiTA review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney diseaseNephrol Dial Transplant Epub20151019
   PubMed Web of Science ®Google Scholar
• RothDNelsonDRBruchfeldAGrazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyLancet2015386100031537154526456905
   PubMed Web of Science ®Google Scholar
• LacombeKRockstrohJHIV and viral hepatitis coinfections: advances and challengesGut201261Suppl 1i47i5822504919
   PubMed Web of Science ®Google Scholar
• JoshiDO’GradyJDieterichDGazzardBAgarwalKIncreasing burden of liver disease in patients with HIV infectionLancet201137797721198120921459211
   PubMed Web of Science ®Google Scholar
• RockstrohJKNelsonMKatlamaCEfficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialLancet HIV201528e319e32726423374
   PubMed Web of Science ®Google Scholar
• YehWFraserIPReitmannCPharmacokinetic interaction of HCV protease inhibitor MK5172 and ritonavir in healthy subjects [abstract 52]HEPDART 2013: Frontiers in Drug Development for Viral HepatitisDecember 8–12, 2013Big Island, HI
   Google Scholar
• TalatyJECaroLYehWPharmacokinetic interaction between the HCV protease inhibitor MK-5172 and efavirenz in normal healthy volunteers [abstract 492]64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)November 1–5, 2013Washington, DC
   Google Scholar
• YehWMarshallWManginEPharmacokinetic interactions between the HCV NS5A inhibitor MK-8742 and efavirenz [abstract 498]Conference on Retroviruses and Opportunistic Infections (CROI)March 3–6, 2014Boston, MA
   Google Scholar
• CaroLTalatyJEGuoZPharmacokinetic interactions between the HCV protease inhibitor MK-5172 and ritonavir-boosted HIV protease inhibitors (atazanavir, lopinavir, darunavir) in healthy volunteers [abstract 487]64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)November 1–5, 2013Washington, DC
   Google Scholar
• YehWYMarshallWMaJRitonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels [abstract 635]Conference on Retroviruses and Opportunistic Infections (CROI)March 3–6, 2014Seattle, WA
   Google Scholar
• CaroLTalatyJEGuoZPharmacokinetic interaction between the HCV protease inhibitor MK-5172 and IV and oral rifampin in healthy volunteers [abstract 495]64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)November 1–5, 2013Washington, DC
   Google Scholar
• CaroLTalatyJEGuoZPharmacokinetic interaction between the HCV protease inhibitor MK-5172 and midazolam, pitavastatin, and atorvastatin in healthy volunteers [abstract 477]Hepatology2013584437A
   Google Scholar
• CaroLMarshallWLFengHPCoadministration of HCV protease inhibitor grazoprevir with HCV NS5A inhibitor elbasvir has no effect on pravastatin but increases rosuvastatin exposure in healthy subjects [abstract 17]16th International Workshop on Clinical Pharmacology of HIV & Hepatitis TherapyMay 26–28, 2015Washington, DC
   Google Scholar
• Package InsertZepatierTM (elbasvir and grazoprevir)Food and Drug Administration2016
   Google Scholar
• PoordadFLawitzEGutierrezJC-swift: Grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis c virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks50th Annual Meeting of the European Association for the Study of the LiverApril 22–26, 2015Vienna, Austria
   Google Scholar
• ZeuzemSRockstrohJKKwoPYPredictors of response to elbasvir/grazoprevir among HCV genotype 1 (GT1)-infected patients: Integrated analysis of phase 2–3 trials [abstract 700]66th Annual Scientific Congress of the American Association for the Study of Liver Diseases (AASLD)November 12–17, 2015San Francisco, CA
   Google Scholar